By: IPP Bureau
Last updated : May 13, 2026 2:18 pm
The partnership covers the entire product lifecycle from early-stage development through commercialization
Shilpa Medicare Limited has signed a long-term development and commercial manufacturing agreement with NXI Therapeutics AG, Switzerland, further strengthening its position in the global CDMO and specialty therapeutics space.
Under the agreement, Shilpa will provide end-to-end CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support for NXI Therapeutics’ immunomodulatory program. The partnership covers the entire product lifecycle from early-stage development through commercialization.
The autoimmune and immune-modulation segment remains one of the fastest-growing therapeutic categories globally, driven by rising disease prevalence and increasing demand for targeted immunotherapies. Through this collaboration, Shilpa expands its participation in innovation-led, high-value pipelines with scalable commercial potential.
This marks the third named partnership announced by Shilpa in the past year, reflecting growing demand from Western biotech companies for its integrated R&D and advanced GMP manufacturing capabilities.
While financial details were not disclosed, the agreement includes milestone-linked expansion opportunities and could evolve into a multi-year commercial supply relationship, subject to successful clinical and regulatory progress.
Vishnukanth Bhutada, Managing Director of Shilpa Medicare, said the collaboration reinforces the company’s transition into a strategic innovation partner for global biotech firms.
“Our integrated development and commercial manufacturing capabilities enable us to support complex assets across the full product lifecycle. We continue to see strong momentum in high-value biologics and specialty therapeutics, strengthening long-term growth visibility for our CDMO platform,” he said.
Dr. Ruben Herrendorff, CEO of NXI Therapeutics AG, said Shilpa’s scientific expertise, quality systems, and scalable GMP manufacturing infrastructure made it a suitable partner for advancing the company’s immunomodulatory program toward clinical and commercial milestones.